Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma
Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma from the February 2009 issue of the British Journal of Ophthalmology.
Please click here to read the full story.
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.